Patents by Inventor Jorge F. Paniagua-Solís
Jorge F. Paniagua-Solís has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9683035Abstract: The present invention concerns therapeutic compositions containing proteins that are the variable regions of IgNAR immunoglobulins, denominated vNAR, that specifically bind and neutralizes cytokines involved in a diversity of process such as inflammation and neovascularization, its ability to reach, bind, and neutralize the activity of one antigenic molecule localized in an immunoprivileged organs, are also described.Type: GrantFiled: July 25, 2016Date of Patent: June 20, 2017Assignee: LABORATORIOS SILANES, S.A. DE C.V.Inventors: Jorge F. Paniagua-Solís, María Teresa Mata-González, Walter J. García-Ubbelohde, Araceli Olguín-Jimenez, Alexei F. Licea-Navarro, Tanya A. Camacho-Villegas, Edna Sanchez-Castrejon
-
Publication number: 20170037122Abstract: The present invention concerns therapeutic compositions containing proteins that are the variable regions of IgNAR immunoglobulins, denominated vNAR, that specifically bind and neutralizes cytokines involved in a diversity of process such as inflammation and neovascularization, its ability to reach, bind, and neutralize the activity of one antigenic molecule localized in an immunoprivileged organs, are also described.Type: ApplicationFiled: July 25, 2016Publication date: February 9, 2017Inventors: Jorge F. Paniagua-Solís, María Teresa Mata-González, Walter J. García-Ubbelohde, Araceli Olguín-Jimenez, Alexei F. Licea-Navarro, Tanya A. Camacho-Villegas, Edna Sanchez-Castrejon
-
Patent number: 9399677Abstract: The present invention concerns therapeutic compositions containing proteins that are the variable regions of IgNAR immunoglobulins, denominated vNAR, that specifically bind and neutralizes cytokines involved in a diversity of process such as inflammation and neovascularization, its ability to reach, bind, and neutralize the activity of one antigenic molecule localized in an immunoprivileged organs, are also described.Type: GrantFiled: July 17, 2013Date of Patent: July 26, 2016Assignee: LABORATORIES SILANES S.A. DE C.V.Inventors: Jorge F. Paniagua-Solís, María Teresa Mata-González, Walter J. García-Ubbelohde, Araceli Olguín-Jimenez, Alexei F. Licea-Navarro, Tanya A. Camacho-Villegas, Edna Sanchez-Castrejon
-
Publication number: 20140044716Abstract: The present invention concerns therapeutic compositions containing proteins that are the variable regions of IgNAR immunoglobulins, denominated vNAR, that specifically bind and neutralizes cytokines involved in a diversity of process such as inflammation and neovascularization, its ability to reach, bind, and neutralize the activity of one antigenic molecule localized in an immunoprivileged organs, are also described.Type: ApplicationFiled: July 17, 2013Publication date: February 13, 2014Applicant: LABORATORIOS SILANES, S.A. DE C.V.Inventors: Jorge F. Paniagua-Solís, María Teresa Mata-González, Walter J. García-Ubbelohde, Araceli Olguín-Jimenez, Alexei F. Lícea-Navarro, Tanya A. Camacho-Villegas, Edna Sanchez-Castrejon
-
Patent number: 8512706Abstract: The present invention is directed to a pharmaceutical composition comprising F(ab?)2 antibody fragments that are preferably free from albumin and of whole antibodies and also substantially free of pyrogens, and an effective amount of a pharmaceutically acceptable carrier. It is also directed to a method for the production of a pharmaceutical composition comprising F(ab?)2 antibody fragments using scrum or blood plasma of a mammal that has been previously immunized as a source of antibodies. The serum or blood plasma is digested with an enzyme pepsin, followed by separation and purification until the pharmaceutical composition of F(ab?)2 fragments is free of albumin and complete antibodies, and substantially free of pyrogens.Type: GrantFiled: November 17, 2011Date of Patent: August 20, 2013Assignee: Instituto Bioclon, S.A. DE C.V.Inventors: Juan López De Silanes, Rita Guadalupe Mancilla Nava, Jorge F. Paniagua-Solís, Alejandro Alagon Cano, Walter J. García-Ubbelohde
-
Patent number: 8496933Abstract: The present invention concerns therapeutic compositions containing proteins that are the variable regions of IgNAR immunoglobulins, denominated vNAR, that specifically bind and neutralizes cytokines involved in a diversity of process such as inflammation and neovascularization, its ability to reach, bind, and neutralize the activity of one antigenic molecule localized in an immunoprivileged organs, are also described.Type: GrantFiled: November 4, 2010Date of Patent: July 30, 2013Assignee: Laboratorios Silanes, S.A. de C.V.Inventors: Jorge F. Paniagua-Solís, María Teresa Mata-González, Walter J. García-Ubbelohde, Araceli Olguín-Jimenez, Alexei F. Licea-Navarro, Tanya A. Camacho-Villegas, Edna Sanchez-Castrejon
-
Publication number: 20120064063Abstract: The present invention is directed to a pharmaceutical composition comprising F(ab?)2 antibody fragments that are preferably free from albumin and of whole antibodies and also substantially free of pyrogens, and an effective amount of a pharmaceutically acceptable carrier. It is also directed to a method for the production of a pharmaceutical composition comprising F(ab?)2 antibody fragments using scrum or blood plasma of a mammal that has been previously immunized as a source of antibodies. The serum or blood plasma is digested with an enzyme pepsin, followed by separation and purification until the pharmaceutical composition of F(ab?)2 fragments is free of albumin and complete antibodies, and substantially free of pyrogens.Type: ApplicationFiled: November 17, 2011Publication date: March 15, 2012Applicant: Instituto Bioclon, S.A. de C.V.Inventors: Juan LOPEZ DE SILANES, Rita G. MANCILLA NAVA, Jorge F. PANIAGUA-SOLÍS, Alejandro ALAGÓN CANO, Walter GARCÍA UBBELOHDE
-
Patent number: 8075893Abstract: The present invention is directed to a pharmaceutical composition comprising F(ab?)2 antibody fragments that are preferably free from albumin and of whole antibodies and also substantially free of pyrogens, and an effective amount of a pharmaceutically acceptable carrier. It is also directed to a method for the production of a pharmaceutical composition comprising F(ab?)2 antibody fragments using serum or blood plasma of a mammal that has been previously immunized as a source of antibodies. The serum or blood plasma is digested with an enzyme pepsin, followed by separation and purification until the pharmaceutical composition of F(ab?)2 fragments is free of albumin and complete antibodies, and substantially free of pyrogens.Type: GrantFiled: December 2, 2008Date of Patent: December 13, 2011Assignee: Instituto Bioclon, S.A. de S.V.Inventors: Juan López De Silanes, Rita Guadalupe Mancilla Nava, Jorge F. Paniagua-Solís, Alejandro Alagon Cano, Walter J. García-Ubbelohde
-
Publication number: 20110129473Abstract: The present invention concerns therapeutic compositions containing proteins that are the variable regions of IgNAR immunoglobulins, denominated vNAR, that specifically bind and neutralizes cytokines involved in a diversity of process such as inflammation and neovascularization, its ability to reach, bind, and neutralize the activity of one antigenic molecule localized in an immunoprivileged organs, are also described.Type: ApplicationFiled: November 4, 2010Publication date: June 2, 2011Applicant: Laboratorios Silanes, S.A. de C.V.Inventors: JORGE F. PANIAGUA-SOLÍS, María Teresa MATA-GONZÁLEZ, Walter J. GARCÍA-UBBELOHDE, Araceli OLGUÍN-JIMENEZ, Alexei F. Licea-Navarro, Tanya A. Camacho-Villegas, Edna Sanchez-Castrejon
-
Publication number: 20090142356Abstract: The present invention is directed to a pharmaceutical composition comprising F(ab?)2 antibody fragments that are preferably free from albumin and of whole antibodies and also substantially free of pyrogens, and an effective amount of a pharmaceutically acceptable carrier. It is also directed to a method for the production of a pharmaceutical composition comprising F(ab?)2 antibody fragments using serum or blood plasma of a mammal that has been previously immunized as a source of antibodies. The serum or blood plasma is digested with an enzyme pepsin, followed by separation and purification until the pharmaceutical composition of F(ab?)2 fragments is free of albumin and complete antibodies, and substantially free of pyrogens.Type: ApplicationFiled: December 2, 2008Publication date: June 4, 2009Applicant: Instituto Bioclon, S.A. De C.V.Inventors: Juan LOPEZ DE SILANES, Rita G. MANCILLA NAVA, Jorge F. PANIAGUA SOLIS, Alejandro ALAGON CANO, Walter GARCIA UBBELOHDE
-
Patent number: 7485303Abstract: The present invention is directed to a pharmaceutical composition comprising F(ab?)2 antibody fragments that are preferably free from albumin and of whole antibodies and also substantially free of pyrogens, and an effective amount of a pharmaceutically acceptable carrier. It is also directed to a method for the production of a pharmaceutical composition comprising F(ab?)2 antibody fragments using serum or blood plasma of a mammal that has been previously immunized as a source of antibodies. The serum or blood plasma is digested with an enzyme pepsin, followed by separation and purification until the pharmaceutical composition of F(ab?)2 fragments is free of albumin and complete antibodies, and substantially free of pyrogens.Type: GrantFiled: October 23, 2003Date of Patent: February 3, 2009Assignee: Instituto Bioclon, S.A. de C.V.Inventors: Juan Lopez de Silanes, Rita G Mancilla-Nava, Jorge F Paniagua-Solis
-
Publication number: 20040166107Abstract: The present invention is directed to a pharmaceutical composition comprising F(ab′)2 antibody fragments that are preferably free from albumin and of whole antibodies and also substantially free of pyrogens, and an effective amount of a pharmaceutically acceptable carrier. It is also directed to a method for the production of a pharmaceutical composition comprising F(ab′)2 antibody fragments using serum or blood plasma of a mammal that has been previously immunized as a source of antibodies. The serum or blood plasma is digested with an enzyme pepsin, followed by separation and purification until the pharmaceutical composition of F(ab′)2 fragments is free of albumin and complete antibodies, and substantially free of pyrogens.Type: ApplicationFiled: October 23, 2003Publication date: August 26, 2004Inventors: Juan Lopez de Silanes, Rita G. Mancilla-Nava, Jorge F. Paniagua-Solis
-
Patent number: 6709655Abstract: The present invention is directed to a pharmaceutical composition comprising F(ab′)2 antibody fragments that are preferably free from albumin and of whole antibodies and also substantially free of pyrogens, and an effective amount of a pharmaceutically acceptable carrier. It is also directed to a method for the production of a pharmaceutical composition comprising F(ab′)2 antibody fragments using serum or blood plasma of a mammal that has been previously immunized, as a source of antibodies. The serum or blood plasma is digested with pepsin, followed by separation and purification until the pharmaceutical composition of F(ab′)2 fragments is free of albumin and complete antibodies, and substantially free of pyrogens.Type: GrantFiled: March 5, 2001Date of Patent: March 23, 2004Assignee: Instituto Bioclon, S.A. de C.V.Inventors: Juan López de Silanes, Rita Mancilla Nava, Jorge F. Paniagua Solis
-
Publication number: 20020164327Abstract: The present invention is directed to a pharmaceutical composition comprising F(ab)2 antibody fragments that are preferably free from albumin and of whole antibodies and also substantially free of pyrogens, and an effective amount of a pharmaceutically acceptable carrier. It is also directed to a method for the production of pharmaceutical composition comprising (F(ab)2 antibody fragments using serum or blood plasma of a mammal that has been previously immunized, as a source of antibodies. The serum or blood plasma is digested with an enzyme pepsin, followed by separation and purification until the pharmaceutical composition of F(ab)2 fragments is free of albumin and complete antibodies, and substantially free of pyrogens.Type: ApplicationFiled: March 5, 2001Publication date: November 7, 2002Inventors: Juan Lopez de Silanes, Rita Mancilla Nava, Jorge F. Paniagua Solis